<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397926</url>
  </required_header>
  <id_info>
    <org_study_id>Neo-Peptide2020</org_study_id>
    <nct_id>NCT04397926</nct_id>
  </id_info>
  <brief_title>Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Hengjia Biotechnology Development co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have&#xD;
      been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are&#xD;
      diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will&#xD;
      be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for&#xD;
      lung cancer, especially for patients with drug resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I clinical study of individualized neoantigen peptides in the treatment of&#xD;
      EGFR mutant non-small cell lung cancer aimed to evaluated the safety and immune response of&#xD;
      the neoantigen vaccine treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the neoantigen vaccine treatment.</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events occurring after the neoantigen vaccine treatment are evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>neoantigen vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Individualized neoantigen peptides vaccine</intervention_name>
    <description>Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks</description>
    <arm_group_label>neoantigen vaccine</arm_group_label>
    <other_name>HJ-N-001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed locally advanced or metastatic non-small-cell lung cancer&#xD;
             (stage III or stage IV), with disease progression after surgery and standard&#xD;
             chemotherapy.&#xD;
&#xD;
          2. With EGFR-TKI sensitive mutations and progresses after receiving EGFR-TKI treatment.&#xD;
&#xD;
          3. The first neoantigen treatment is more than 4 weeks away from the previous&#xD;
             chemotherapy or clinical research drug treatment.&#xD;
&#xD;
          4. The first neoantigen treatment is more than 4 weeks away from the previous&#xD;
             radiotherapy or EGFR-TKI treatment.&#xD;
&#xD;
          5. At least one measurable disease according to RECIST v1.1.&#xD;
&#xD;
          6. 18 years of age or older&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
          8. ECOG Performance Status 0 or 1.&#xD;
&#xD;
          9. Have adequate organ function, as measured by laboratory values: Lymphocyte ratio&gt;20%;&#xD;
             WBC&gt;3.0×10^9/L; alanine aminotransferase(ALT) and aspartate aminotransferase (AST)≤2.5&#xD;
             × ULN; If the patient has liver metastases, ALT and AST≤5 × ULN; Alkaline&#xD;
             phosphatase（ALP）≤2.5 × ULN; total serum bilirubin (TBIL) &lt; 1.5 × ULN; Urea&#xD;
             nitrogen（BUN）≤1.5 × ULN; Creatinine（Cr）≤ULN; Normal blood coagulation function, urine&#xD;
             routine, and electrocardiogram (ECG).&#xD;
&#xD;
         10. Available tumor specimen for sequencing and EGFR gene mutation frequency&gt;5%.&#xD;
&#xD;
         11. Ability to find more than 3 available neoantigen epitopes.&#xD;
&#xD;
         12. No previous immunotherapy, including anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or&#xD;
             targeting another stimulatory or co-suppressive T cell receptor (eg CTLA-4, OX-40,&#xD;
             CD137 ) drug therapy, peptide / mRNA neoantigen immunotherapy and cell therapy.&#xD;
&#xD;
         13. Ability to follow research and follow-up procedures.&#xD;
&#xD;
         14. Able to understand and willing to sign an IRB approved written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suffering from other known malignant tumors, which are progressing or require active&#xD;
             treatment within the past 5 years.&#xD;
&#xD;
          2. History of immunodeficiency disorder or autoimmune condition requiring active&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
          3. Actively infectious condition including hepatitis; HIV antibody positive; Treponema&#xD;
             pallidum antibody positive.&#xD;
&#xD;
          4. With uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated&#xD;
             drainage.&#xD;
&#xD;
          5. Known, active, untreated CNS metastasis and / or cancerous meningitis.&#xD;
&#xD;
          6. Mental illness or substance abuse disorder, which will interfere with the cooperation&#xD;
             with research requirements.&#xD;
&#xD;
          7. Evidence of Liver and kidney dysfunction, severe heart disease, coagulation&#xD;
             dysfunction and damage to hematopoietic function.&#xD;
&#xD;
          8. Receive systemic cytotoxic chemotherapy or test drugs for metastatic NSCLC (excluding&#xD;
             EGFR-TKI) within the past month.&#xD;
&#xD;
          9. Receive radiotherapy within 2 weeks before the start of neoantigen treatment or&#xD;
             chemotherapy within 4 weeks. Participants must recover from all&#xD;
             radiochemotherapy-related toxicity without the use of corticosteroids and have not had&#xD;
             radiation pneumonitis. Palliative radiotherapy allowed for symptom control must be&#xD;
             completed at least 2 weeks before the first medication, and no additional radiotherapy&#xD;
             is planned for the same lesion.&#xD;
&#xD;
         10. Patients participated in other anticancer drug clinical trials within 4 weeks&#xD;
&#xD;
         11. A psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements as determined by the investigator from the medical history, physical&#xD;
             exam, and/or medical record or the investigator believes that there are other reasons&#xD;
             that are not suitable for inclusion.&#xD;
&#xD;
         12. Pregnant and/or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zhang, M.D.</last_name>
    <phone>86-20-8734-3894</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, M.D.</last_name>
      <phone>86-20-8734-3894</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang, MD</investigator_full_name>
    <investigator_title>Director of Oncology</investigator_title>
  </responsible_party>
  <keyword>neoantigen peptides vaccine，non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

